The Workplan

  • WP1

     

    ETHICS REQUIREMENTS

    will ensure compliance with the ‘ethics requirements’.

  • WP2

    PHENOTYPING NEUROPATHIC AND CANCER PAIN PATIENTS

    will perform a thorough characterisation of neuropathy and cancer pain patients using standardised set of clinical, neurophysiologic and neuropathologic tools.

     

    WP2

  • WP3

     

    ELECTROPHYSIOLOGICAL MEASURES OF PAIN MAGNITUDE IN THE PERIPHERAL NERVOUS SYSTEM

    aims to: identify and characterise patients with peripheral neuropathic pain suitable for microneurographic recordings; perform microneurographic recording of spontaneous discharge of different classes of nociceptors and quantify their excitability in pain patients and healthy subjects; establish a spontaneous pain model by combining nociceptor sensitisation and inflammation; compare microneurography results to classic readouts (Quantitative Sensory Testing, Nerve Conduction Studies, Pain-related Evoked Potentials).

  • WP4

    GENETICS OF PAIN

    will investigate the genetic bases of neuropathic pain, cancer pain and responsiveness to analgesics.

     

    WP4

  • WP5

     

    IN VITRO FUNCTIONAL ANALYSES OF PAIN CAUSATIVE GENE MUTATIONS

    aims to in vitro analyse the pathogenic potential of mutations in sodium channel genes identified in patients with neuropathic pain through clinical and genetic assessment; to use functional proteomics for identification and characterization of peripheral sodium channel signalling complexes.

  • WP6

    IONFLUX HIGH-THROUGHPUT SCREENING OF ANALGESIC COMPOUNDS

    aims to perform in vitro high-throughput screening of conventional and proprietary analgesic compounds targeting ion channels

     

    WP6

  • WP7

     

    CREATION AND CHARACTERISATION OF PAIN-RELATED SODIUM CHANNEL CRISPR-CAS MOUSE MODELS

    aims to create and characterise the first transgenic mouse models of sodium-channel-related neuropathic pain.

  • WP8

    CREATION AND ASSESSMENT OF NEUROPATHIC CHRONIC ITCH MOUSE MODEL

    aims to develop and evaluate in in vitro and in vivo models of chronic itch and to validate treatment in mouse models

     

    WP8

  • WP9

     

    TRAINING ACTIVITIES

    aims at providing a substrate to training activity through the different sectors and research units.

  • WP10

    DISSEMINATION, COMMUNICATION AND PUBLIC ENGAGEMENT ACTIVITIES

    aims to spread PAIN-Net to the largest audience in line with Open Innovation, Open Science, Open to the World strategy; carry out information and awareness initiatives; to promote communication towards the general public and to increase awareness of science.

     

    WP10

  • WP11

     

    EXPLOITATION AND INNOVATION

    aims to identify exploitable results and plan an exploitation strategy; to contribute to the European Innovation Union.

  • WP12

    PROJECT MANAGEMENT

    will link together the project components, to maintain communication with the EC, to establish and adopt common operational and research and training procedures, to ensure consistent technical reporting to the REA, to monitor compliance of all beneficiaries with their obligations, to ensure a correct and timely financial management and reporting, to administer the EC contribution, to ensure respect of ethical issues and attention paid to gender issues.

     

    WP12